Loading...

Sosei Group

DB:JSS
Snowflake Description

Reasonable growth potential with mediocre balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
JSS
DB
¥163B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Sosei Group Corporation, a biopharmaceutical company, discovers, develops, and commercializes biopharmaceutical products worldwide. The last earnings update was 82 days ago. More info.


Add to Portfolio Compare Print
  • Sosei Group has significant price volatility in the past 3 months.
JSS Share Price and Events
7 Day Returns
8.3%
DB:JSS
0.7%
DE Pharmaceuticals
0.2%
DE Market
1 Year Returns
-
DB:JSS
-29%
DE Pharmaceuticals
-10.9%
DE Market
JSS Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Sosei Group (JSS) 8.3% 28.8% 55.6% - - -
DE Pharmaceuticals 0.7% -4.4% -16% -29% -24.8% 8.2%
DE Market 0.2% -2.5% -2% -10.9% 8.9% 6.3%
1 Year Return vs Industry and Market
  • No trading data on JSS.
  • No trading data on JSS.
Price Volatility
JSS
Industry
5yr Volatility vs Market
Related Companies

Sorry, no analysis for Sosei Group's competitors could be found in our database.

Value

 Is Sosei Group undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Sosei Group. This is due to cash flow or dividend data being unavailable. The share price is €17.04.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Sosei Group's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Sosei Group's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:JSS PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in JPY ¥-90.76
TSE:4565 Share Price ** TSE (2019-06-18) in JPY ¥2128
Germany Pharmaceuticals Industry PE Ratio Median Figure of 6 Publicly-Listed Pharmaceuticals Companies 27.59x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.63x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Sosei Group.

DB:JSS PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= TSE:4565 Share Price ÷ EPS (both in JPY)

= 2128 ÷ -90.76

-23.45x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Sosei Group is loss making, we can't compare its value to the DE Pharmaceuticals industry average.
  • Sosei Group is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Sosei Group's expected growth come at a high price?
Raw Data
DB:JSS PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -23.45x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
44.1%per year
Europe Pharmaceuticals Industry PEG Ratio Median Figure of 35 Publicly-Listed Pharmaceuticals Companies 2x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.46x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Sosei Group, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Sosei Group's assets?
Raw Data
DB:JSS PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in JPY ¥544.90
TSE:4565 Share Price * TSE (2019-06-18) in JPY ¥2128
Germany Pharmaceuticals Industry PB Ratio Median Figure of 8 Publicly-Listed Pharmaceuticals Companies 1.76x
Germany Market PB Ratio Median Figure of 576 Publicly-Listed Companies 1.77x
DB:JSS PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= TSE:4565 Share Price ÷ Book Value per Share (both in JPY)

= 2128 ÷ 544.90

3.91x

* Primary Listing of Sosei Group.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Sosei Group is overvalued based on assets compared to the DE Pharmaceuticals industry average.
X
Value checks
We assess Sosei Group's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Sosei Group has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Sosei Group expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
44.1%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Sosei Group expected to grow at an attractive rate?
  • Sosei Group's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Sosei Group's earnings growth is expected to exceed the Germany market average.
  • Sosei Group's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:JSS Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:JSS Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts 44.1%
DB:JSS Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts 17.5%
Germany Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 17%
Germany Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 3.8%
Germany Market Earnings Growth Rate Market Cap Weighted Average 12.7%
Germany Market Revenue Growth Rate Market Cap Weighted Average 5%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:JSS Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (5 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in JPY Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:JSS Future Estimates Data
Date (Data in JPY Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 8,944 -2,418 1
2022-12-31 8,431 -2,664 1
2021-12-31 9,723 955 3,200 2
2020-12-31 10,873 1,975 872 3
2019-12-31 7,645 2,009 -4,715 3
DB:JSS Past Financials Data
Date (Data in JPY Millions) Revenue Cash Flow Net Income *
2018-12-31 3,550 -6,047 -6,918
2018-09-30 3,444 -5,640 -5,483
2018-06-30 5,005 -3,358 -4,202
2018-03-31 6,955 -2,167 -2,654
2017-12-31 8,060 609 -2,608
2017-09-30 8,376 211 -1,338
2017-06-30 6,603 -1,102 -1,547
2017-03-31 18,901 12,856 9,311
2016-12-31 17,528 11,424 6,481
2016-09-30 21,450 15,378 9,514
2016-06-30 22,658 17,064 10,508
2016-03-31 8,151 4,471 -1,432

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Sosei Group's earnings are expected to grow significantly at over 20% yearly.
  • Sosei Group's revenue is expected to grow by 17.5% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:JSS Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (5 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from Sosei Group Company Filings, last reported 5 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:JSS Future Estimates Data
Date (Data in JPY Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 -31.70 -31.70 -31.70 1.00
2022-12-31 -35.00 -35.00 -35.00 1.00
2021-12-31 41.90 41.90 41.90 1.00
2020-12-31 11.43 39.30 -30.20 3.00
2019-12-31 -61.90 -61.90 -61.90 1.00
DB:JSS Past Financials Data
Date (Data in JPY Millions) EPS *
2018-12-31 -90.76
2018-09-30 -73.19
2018-06-30 -57.70
2018-03-31 -37.55
2017-12-31 -38.03
2017-09-30 -19.76
2017-06-30 -22.88
2017-03-31 137.79
2016-12-31 96.04
2016-09-30 141.97
2016-06-30 163.43
2016-03-31 -23.39

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Sosei Group is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Sosei Group's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Sosei Group has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Sosei Group performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Sosei Group's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Sosei Group does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Sosei Group's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Sosei Group's 1-year growth to the DE Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Sosei Group's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Sosei Group Company Filings, last reported 5 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:JSS Past Revenue, Cash Flow and Net Income Data
Date (Data in JPY Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 3,550.00 -6,918.00 2,387.00 6,863.00
2018-09-30 3,444.00 -5,483.00 2,981.00 6,893.00
2018-06-30 5,005.00 -4,202.00 3,366.00 5,690.00
2018-03-31 6,955.00 -2,654.00 3,569.00 4,935.00
2017-12-31 8,060.00 -2,608.00 3,206.00 4,346.00
2017-09-30 8,376.00 -1,338.00 2,755.00 3,782.00
2017-06-30 6,603.00 -1,547.00 2,518.00 3,388.00
2017-03-31 18,901.00 9,311.00 2,746.00 3,218.00
2016-12-31 17,528.00 6,481.00 3,625.00 3,507.00
2016-09-30 21,450.00 9,514.00 3,527.00 3,677.00
2016-06-30 22,658.00 10,508.00 3,192.00 3,971.00
2016-03-31 8,151.00 -1,432.00 2,482.00 3,916.00
2015-12-31 10,461.00 2,599.00 2,882.00 3,072.00
2015-09-30 5,646.00 -255.00 2,499.00 2,313.00
2015-06-30 4,010.00 -118.00 2,259.00 1,362.00
2015-03-31 3,671.00 568.00 1,940.00 557.00
2014-12-31 1,169.00 2,191.00 -598.00 527.00
2014-09-30 1,051.00 1,593.40 934.78 220.00
2014-06-30 2,236.00 2,030.00 396.00 375.00
2014-03-31 2,069.00 1,526.00 880.00 305.00
2013-12-31 1,947.64 -848.85 1,825.39 205.00
2013-09-30 2,323.64 -507.11 712.29 430.00
2013-06-30 1,824.00 -601.00 628.00 385.00
2013-03-31 1,958.00 -646.00 613.00 385.00
2012-12-31 1,889.36 -787.15 -218.39 407.00
2012-09-30 1,276.36 -1,378.15 -227.39 407.00
2012-06-30 827.00 -2,076.00 785.00 227.00

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Sosei Group has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Sosei Group has efficiently used its assets last year compared to the DE Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Sosei Group improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Sosei Group's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Sosei Group has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Sosei Group's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Sosei Group's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Sosei Group is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Sosei Group's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Sosei Group's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 3.2x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Sosei Group Company Filings, last reported 5 months ago.

DB:JSS Past Debt and Equity Data
Date (Data in JPY Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 41,580.00 6,964.00 18,760.00
2018-09-30 45,623.00 7,750.00 21,327.00
2018-06-30 46,469.00 8,438.00 25,042.00
2018-03-31 48,886.00 9,173.00 28,281.00
2017-12-31 50,653.00 9,904.00 32,137.00
2017-09-30 30,427.00 10,635.00 12,413.00
2017-06-30 29,887.00 11,317.00 12,983.00
2017-03-31 28,358.00 6,900.00 13,899.00
2016-12-31 29,866.00 7,386.00 15,441.00
2016-09-30 26,762.00 7,870.00 15,680.00
2016-06-30 29,319.00 8,354.00 20,649.00
2016-03-31 23,268.00 8,837.00 10,068.00
2015-12-31 29,848.00 9,319.00 11,939.00
2015-09-30 23,289.00 9,799.00 5,522.00
2015-06-30 16,364.00 19,938.00 6,875.00
2015-03-31 14,894.00 19,877.00 5,573.00
2014-12-31 15,204.00 15.00 7,865.00
2014-09-30 14,547.00 0.00 7,592.00
2014-06-30 14,215.00 0.00 7,396.00
2014-03-31 14,354.00 0.00 7,214.00
2013-12-31 6,369.00 0.00 3,293.00
2013-09-30 6,583.11 0.00 2,226.31
2013-06-30 5,930.00 0.00 2,273.00
2013-03-31 6,510.00 0.00 2,537.00
2012-12-31 6,959.00 0.00 2,398.00
2012-09-30
2012-06-30 6,481.00 0.00 1,204.00
  • Sosei Group's level of debt (16.7%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0% vs 16.7% today).
  • Operating cash flow is negative therefore debt is not well covered.
  • Unable to confirm if the interest payments on Sosei Group's debt are well covered by earnings due to lack of past financial data.
X
Financial health checks
We assess Sosei Group's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Sosei Group has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Sosei Group's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Sosei Group dividends. Estimated to be 0% next year.
If you bought €2,000 of Sosei Group shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Sosei Group's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Sosei Group's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:JSS Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
Germany Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 5 Stocks 3.4%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3.2%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.5%
Germany Top 25% Dividend Yield 75th Percentile 3.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:JSS Future Dividends Estimate Data
Date (Data in ¥) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 2.00
2019-12-31 0.00 3.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Sosei Group has not reported any payouts.
  • Unable to verify if Sosei Group's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Sosei Group's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Sosei Group has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Sosei Group's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Sosei Group's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Sosei Group afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Sosei Group has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Sosei Group's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Shinichi Tamura
COMPENSATION ¥191,000,000
AGE 69
TENURE AS CEO 0.4 years
CEO Bio

Mr. Shinichi Tamura is the founder of Sosei Co. Ltd. and has been its President and Representative Executive Officer since November 2006. Mr. Tamura is the Founder of Sosei Group Corporation and has been its Executive Chairman since June 24, 2016 and has been its Representative Executive Officer since June 2005. He has been President and CEO of Sosei Group since January 1, 2019. He served as the Group Chairman, Chief Executive Officer and President of Sosei Group Corporation since June 1990 until June 24, 2016. Mr. Tamura advised various companies e.g. Genentech, GenPharm, Geron, IDEC, Pharmacyclics, Vernalis among others. Prior to that, he worked for Fujisawa Pharmaceutical Co., Ltd. at various positions in Planning. Mr. Tamura serves as a Director of Sosei Co. Ltd. He is a Tokyo University graduate with M.S. in Biochemistry and a major in Cultural Anthropology.

CEO Compensation
  • Insufficient data for Shinichi to compare compensation growth.
  • Shinichi's remuneration is lower than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Sosei Group management team in years:

1.2
Average Tenure
59.5
Average Age
  • The average tenure for the Sosei Group management team is less than 2 years, this suggests a new team.
Management Team

Shinichi Tamura

TITLE
Founder
COMPENSATION
¥191M
AGE
69
TENURE
0.4 yrs

Chris Cargill

TITLE
Executive Officer
AGE
34
TENURE
1 yrs

Kazuhiko Yoshizumi

TITLE
Executive Officer
AGE
64
TENURE
1.4 yrs

Shinichiro Nishishita

TITLE
Vice President of Corporate Communication Department

Pippa Evans

TITLE
Group Head of Human Resources

Malcolm Weir

TITLE
Executive Officer
AGE
60
TENURE
4 yrs

Tim Tasker

TITLE
Executive Officer
AGE
54
TENURE
1.4 yrs

Tadayoshi Yasui

TITLE
Executive Officer & Executive VP
AGE
59
TENURE
0.3 yrs

Barry Kenny

TITLE
Chief Business Officer of Business Development

Miles Congreve

TITLE
Senior VP & Head of Drug Discovery
Board of Directors Tenure

Average tenure and age of the Sosei Group board of directors in years:

1.5
Average Tenure
66.5
Average Age
  • The average tenure for the Sosei Group board of directors is less than 3 years, this suggests a new board.
Board of Directors

Shinichi Tamura

TITLE
Founder
COMPENSATION
¥191M
AGE
69
TENURE
3 yrs

Tomohiro Tohyama

TITLE
External Director
AGE
68
TENURE
8 yrs

Julia Gregory

TITLE
External Director
AGE
66
TENURE
2 yrs

Kuniaki Kaga

TITLE
Independent External Director
AGE
67
TENURE
1 yrs

David Roblin

TITLE
Independent External Director
AGE
52
TENURE
1 yrs

Noriaki Nagai

TITLE
External Director
AGE
61
TENURE
0.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Sosei Group's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Sosei Group has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Sosei Group Corporation, a biopharmaceutical company, discovers, develops, and commercializes biopharmaceutical products worldwide. Its marketed products include Ultibro/Breezhaler, Utibron/Neohaler, Seebri/Breezhaler, and Seebri/Neohaler for the treatment of chronic obstructive pulmonary disease (COPD); NorLevo0.75mg, an emergency contraceptive; and ORAVI, an Oropharyngeal candidiasis. The company’s product pipeline consists of AZD4635, an adenosine A2a antagonist, which is in Phase II clinical trial for the treatment of solid tumors; AZD4635 which is also in Phase 1b/2 clinical study in combination with MEDI9447 (an anti-CD73 antibody developed by MedImmune) for the treatment of non-small cell lung cancer; HTL0016878, a muscarinic M4 agonist, which is in Phase I clinical trial for the treatment of Alzheimer’s disease; and dual M1/M4 agonist, which is in pre-clinical stage for the treatment of Alzheimer’s disease. It also develops HTL0014242, a mGlu5 small molecule negative-allosteric modulator, which is in Phase I clinical trial for the treatment of certain neurological order; SSTR agonist, a novel somatostatin peptide agonist, which is in Phase I clinical trial for the treatment of endocrine disorders; HTL0022562, a calcitonin gene related peptide antagonist, which is in pre-clinical stage for the treatment of migraine and other severe headaches; GLP-1 antagonist, a potent glucagon-like peptide-1 antagonist, which is in pre-clinical stage for the treatment of severe hypoglycaemia in rare diseases; and GLP-2 agonist, a potent glucagon-like peptide-2 agonist, which is in pre-clinical stage for the treatment of intestinal disorders. In addition, the company is developing biopharmaceuticals for the treatment of Alzheimer's disease, cancer, metabolic diseases, and other indications. The company has a strategic collaboration with Kymab and PeptiDream Inc. Sosei Group Corporation was founded in 1990 and is headquartered in Tokyo, Japan.

Details
Name: Sosei Group Corporation
JSS
Exchange: DB
Founded: 1990
¥1,338,702,166
76,375,832
Website: http://soseiheptares.com
Address: Sosei Group Corporation
PMO Hanzomon,
11th Floor,
Tokyo,
102-0083,
Japan
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
TSE 4565 Common Shares The Tokyo Stock Exchange JP JPY 29. Jul 2004
OTCPK SOLT.F Common Shares Pink Sheets LLC US USD 29. Jul 2004
DB JSS Common Shares Deutsche Boerse AG DE EUR 29. Jul 2004
Number of employees
Current staff
Staff numbers
169
Sosei Group employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/06/18 22:39
End of day share price update: 2019/06/18 00:00
Last estimates confirmation: 2019/05/22
Last earnings filing: 2019/03/28
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.